MedTrace Logo

Long-Term Risk of Gout in Living Kidney Donors

NCT07546643 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50000

Last updated 2026-04-23

No results posted yet for this study

Summary

This population-based, matched, retrospective cohort study will evaluate the long-term risk of gout among living kidney donors compared with matched healthy nondonors, using linked administrative health care databases from Ontario, Alberta, and British Columbia. Living kidney donors who donated between 1992 and 2024 will be identified and matched 1:10 to a carefully selected population of healthy nondonors based on baseline characteristics. The primary outcome is the first health care encounter with a diagnosis of gout. Secondary outcomes include receipt of a dispensed prescription for the composite of allopurinol, colchicine, or febuxostat, and each medication separately. The findings will provide evidence to inform clinical guidelines, support informed decision-making among potential donors and recipients, and guide counselling by transplant clinicians.

Conditions

  • Living Kidney Donation
  • Living Kidney Donor
  • Gout
  • Gout and Hyperuricemia

Interventions

PROCEDURE

Living kidney donation

Receipt of a nephrectomy for living kidney donation

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
105 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1992-07-01
Primary Completion
2024-03-31
Completion
2025-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07546643 on ClinicalTrials.gov